Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 8Terminated 4Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Lung Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Melanoma 3Leukemia 3Glioblastoma 3Cholangiocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Gliosarcoma 2Glioma 2Congenital Abnormalities 2Colonic Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stomatitis 1Primary Myelofibrosis 1Polycythemia Vera 1Pleural Effusion, Malignant 1Pain 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Drug Therapy × Clear all
NCT00321698 2024-08-29

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

OHSU Knight Cancer Institute

Phase 1/2 Terminated
25 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT00004026 2020-10-19

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

CTI BioPharma

Phase 2 Terminated
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT00089856 2008-11-05

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Cell Genesys

Phase 3 Terminated
626 enrolled
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00133224 2008-09-23

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Cell Genesys

Phase 3 Terminated
408 enrolled
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡